Eledon Pharmaceuticals (Nasdaq:ELDN) - Aandelenkoers, Nieuws & Analyse

ELDN Overzicht aandelen

Eledon Pharmaceuticals, Inc. is een biotechnologiebedrijf in een klinische fase. Meer informatie

ELDN fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

De winst zal naar verwachting de komende drie jaar met gemiddeld 33% per jaar dalen.

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Volatiele aandelenkoers in de afgelopen 3 maanden

+ 1 meer risico

Eledon Pharmaceuticals, Inc. Concurrenten

Mersana Therapeutics

NasdaqGS:MRSN

US$247.1m

Benitec Biopharma

NasdaqCM:BNTC

US$235.6m

aTyr Pharma

NasdaqCM:ATYR

US$261.9m

Fate Therapeutics

NasdaqGM:FATE

US$275.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Eledon Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$4.25
52 Week Hoogtepunt	US$5.54
52 Week Laag	US$1.11
Bèta	0.77
11 maand verandering	25.37%
3 maanden verandering	49.12%
1 Jaar Verandering	254.17%
33 jaar verandering	-13.09%
5 jaar verandering	-61.29%
Verandering sinds IPO	-96.30%

Recent nieuws en updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

Rendement voor aandeelhouders

	ELDN	US Biotechs	US Markt
7D	9.5%	4.0%	2.0%
1Y	254.2%	18.0%	32.4%

Rendement versus industrie: ELDN overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 18 % opleverde.

Rendement versus markt: ELDN overtrof de US markt, die het afgelopen jaar een rendement opleverde van 32.4 %.

Prijsvolatiliteit

Is ELDN's price volatile compared to industry and market?
ELDN volatility
ELDN Average Weekly Movement	10.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van ELDN is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 11% ) van ELDN is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	20	DA Gros	eledon.com

Eledon Pharmaceuticals, Inc. is een biotechnologiebedrijf in een klinische fase. Het bedrijf gebruikt zijn immunologische expertise in het aanpakken van de CD40 Ligand (CD40L, ook wel CD154 genoemd) pathway om therapieën te ontwikkelen om getransplanteerde organen te beschermen en afstoting te voorkomen, en om amyotrofische laterale sclerose (ALS) te behandelen. De hoofdverbinding van het bedrijf in ontwikkeling is tegoprubart, een IgG1 en anti-CD40L antilichaam met hoge affiniteit voor CD40 Ligand, een biologisch doelwit met therapeutisch potentieel.

Eledon Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Eledon Pharmaceuticals zich tot de beurswaarde?
ELDN fundamentele statistieken
Marktkapitalisatie	US$239.55m
Inkomsten(TTM)	-US$24.55m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-10.3x

Koers/Winstverhouding

Is ELDN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ELDN resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$24.55m
Inkomsten	-US$24.55m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.41
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ELDN op de lange termijn?

Bekijk historische prestaties en vergelijking

ELDN Overzicht aandelen

Risicoanalyse

Eledon Pharmaceuticals, Inc. Concurrenten

NasdaqGS:MRSN

US$247.1m

NasdaqCM:BNTC

US$235.6m

NasdaqCM:ATYR

US$261.9m

NasdaqGM:FATE

US$275.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Price target decreased by 20% to US$12.50

Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Recent updates

Price target decreased by 20% to US$12.50

Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024

New major risk - Shareholder dilution

Price target decreased by 10% to US$14.00

Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding

New minor risk - Share price stability

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer

Insufficient new directors

Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors

Price target decreased by 10% to US$16.50

Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023

Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

New major risk - Financial position

Eledon Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Price target decreased to US$19.40

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Eledon Pharmaceuticals, Inc. Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1B Trial Evaluating Tegoprubart in Kidney Transplantation

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

Eledon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$28.80

Price target decreased to US$29.75

Senior VP of Administration & Principal Accounting Officer Jon Kuwahara has left the company

Chief Financial Officer recently bought US$89k worth of stock

Eledon Pharmaceuticals, Inc. Announces Update on Development Strategy for AT-1501 in Renal Transplantation

Eledon gives update on development strategy for AT-1501 in renal transplantation

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Eledon Pharmaceuticals, Inc. Announces Appointments of Paul Little as Chief Financial Officer

New 90-day low: US$12.66

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from NASDAQ Composite Index

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

New 90-day low: US$14.76

Price target raised to US$35.00

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Novus Therapeutics, Inc. Appoints June Lee to the Board of Directors

Novus Therapeutics EPS misses by $3.76

Novus Therapeutics, Inc. to Report Q3, 2020 Results on Nov 16, 2020

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis